StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)

Close on Nov 17, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Monte Rosa Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $170.69M, up 32.0% year over year. For fiscal 2025 it was $141.50M, up 16.4% from the year before. The highest annual figure on record is $141.50M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$141.50M+16.4%
FY2024Dec 31, 2024$121.56M+9.2%
FY2023Dec 31, 2023$111.27M+30.8%
FY2022Dec 31, 2022$85.06M+48.8%
FY2021Dec 31, 2021$57.16M+138.1%
FY2020Dec 31, 2020$24.01M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$47.96M+56.5%
Q1 FY2026Mar 31, 2026$44.07M+36.9%
Q4 FY2025Dec 31, 2025$41.98M+8.0%
Q3 FY2025Sep 30, 2025$36.68M+32.8%
Q2 FY2025Jun 30, 2025$30.65M+9.3%
Q1 FY2025Mar 31, 2025$32.19M+19.1%
Q4 FY2024Dec 31, 2024$38.87M+43.2%
Q3 FY2024Sep 30, 2024$27.62M-2.4%
Q2 FY2024Jun 30, 2024$28.06M-3.5%
Q1 FY2024Mar 31, 2024$27.03M+1.0%
Q4 FY2023Dec 31, 2023$27.14M+9.1%
Q3 FY2023Sep 30, 2023$28.31M+32.6%
Q2 FY2023Jun 30, 2023$29.08M+38.9%
Q1 FY2023Mar 31, 2023$26.76M+49.3%
Q4 FY2022Dec 31, 2022$24.87M+37.2%
Q3 FY2022Sep 30, 2022$21.34M+41.2%
Q2 FY2022Jun 30, 2022$20.94M+43.0%
Q1 FY2022Mar 31, 2022$17.92M+93.2%
Q4 FY2021Dec 31, 2021$18.13M+83.8%
Q3 FY2021Sep 30, 2021$15.12M+176.2%
Q2 FY2021Jun 30, 2021$14.64M+201.5%
Q1 FY2021Mar 31, 2021$9.27M–
Q4 FY2020Dec 31, 2020$9.86M–
Q3 FY2020Sep 30, 2020$5.47M–
Q2 FY2020Jun 30, 2020$4.86M–

More Monte Rosa Therapeutics figures

See a number that looks wrong?